ArticleMedicine2025
A two-sample Mendelian randomization analysis of the impact of GABA receptor subtypes on human height.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gamma-aminobutyric acid (GABA) supplements are increasingly marketed for promoting growth, yet the genetic influence of GABA receptor subtypes on human height remains unexplored. This Mendelian randomization (MR) study aimed to investigate the causal relationships between genetically predicted plasma levels of 2 GABA receptor subtypes (GABRA4 and GABRB2), and height-related outcomes, including body height (BH), idiopathic short stature (ISS), and constitutional tall stature (CTS). This study employed a two-sample MR approach to assess the causal effect of GABA receptor subtypes, specifically GABRA4 and GABRB2, on height-related traits. Genetic instruments for GABRA4 and GABRB2 were obtained from the UK Biobank Pharma Proteomics Project and INTERVAL study. Outcome data, including BH, ISS, and CTS, were sourced from large-scale genome-wide association studies, including datasets from the FINNGEN study, European Bioinformatics Institute (EBI), and the GIANT Consortium. The inverse variance-weighted method was employed as the primary analytical approach to estimate the causal effects. Sensitivity analyses included MR-Egger regression and the weighted median method to assess for pleiotropy and ensure robustness. Additionally, the MR-PRESSO method was applied to identify and exclude outlier SNPs with potential horizontal pleiotropy, further enhancing the reliability of the causal estimates. Our MR analysis revealed no significant associations between genetically predicted GABRA4 and height-related outcomes after Benjamini-Hochberg correction. In contrast, GABRB2 was positively associated with BH in the EBI dataset (β = 0.0203; P = 1.737e-05), but this association was not replicated in the other datasets. No significant associations were observed for GABRB2 with ISS (OR = 0.82, P = .165) or CTS (OR = 1.47, P = .259). Sensitivity analyses did not suggest any pleiotropic effects. Our MR analysis did not reveal significant causal relationships between GABRA4 or GABRB2 and height-related outcomes, such as BH, ISS, and CTS. To the best of our knowledge, this is the first study to explore the GABA receptor subtypes on human height. This novel approach provides important evidence refuting any direct association between these receptors and human height, filling a critical gap in the existing literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.